Communiqués enGene Therapeutics Inc.

Actions

ENGN

CA29286X1015

Recherche biotechnologique et médicale

Cours en clôture Nasdaq 10/09/2026			Varia. 5j.	Varia. 1 janv.
1,770 ^USD	-4,32%		-2,75%	-80,40%

08/09	EnGene Therapeutics Inc. présente ses dernières avancées cliniques	CI
08/09	EnGene Therapeutics Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 31 juillet 2026	CI

Communiqués

07/04	EnGene Announces Name Change to enGene Therapeutics Inc.	BU
09/03	EnGene : Quarterly Report for Quarter Ending January 31, 2026 (Form 10-Q)	PU
09/03	EnGene Reports First Quarter 2026 Financial Results and Provides Business Update	BU
20/02	EnGene to Participate in Upcoming Investor Conferences	BU
19/02	EnGene : Amendment to Annual Report (Form 10-K/A)	PU
04/02	EnGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026	BU
20/01	EnGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.	BU
22/12	EnGene Reports Full Year 2025 Financial Results and Provides Business Update	BU
02/12	EnGene : Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness	PU
02/12	EnGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness	BU
25/11	EnGene to Present at the Piper Sandler 37th Annual Healthcare Conference	BU
13/11	EnGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants	BU
12/11	EnGene Announces Proposed Public Offering of Common Shares	BU
12/11	EnGene Holdings Inc. - Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months	AQ
11/11	Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months	BU
10/11	EnGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial	BU
06/11	EnGene to Participate in Upcoming Investor Conferences	BU
04/11	EnGene Named a BioSpace 2026 Best Places to Work Winner	BU
01/10/25	EnGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	BU
30/09/25	EnGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer	BU
11/09/25	EnGene Reports Third Quarter 2025 Financial Results and Provides Business Update	BU
03/09/25	EnGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort	BU
27/08/25	EnGene to Participate in Upcoming Investor Conferences	BU
04/08/25	EnGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	BU
08/07/25	EnGene Announces Board and Leadership Appointments to Support Commercial Readiness	BU